title: Plasma adiponectin and E-selectin concentrations in patients with coronary heart disease and newly diagnosed disturbances of glucose metabolism.
abstract: OBJECTIVE
  Adiponectin is a fat derived hormone, which enhances insulin sensitivity. In experimental studies adiponectin was shown to have antiatherogenic properties by suppressing endothelial expression of adhesion molecules. Therefore, the aim of the study was to evaluate plasma adiponectin and E-selectin concentrations in patients with coronary artery disease and impaired glucose metabolism and evaluation of their relationship with selected anthropometric, biochemical and clinical parameters.
  
  
  METHODS
  The study group consisted of 62 patients with coronary heart disease, without previous diagnosis of diabetes mellitus (mean age 48.6 +/- 6.0 years; mean BMI 28.6 +/- 3.13 kg/m2). In the studied group the OGTT with glucose and insulin estimation was performed and insulin resistance index (HOMA-IR) was calculated. In the fasting state, the plasma adiponectin, soluble form of E-selectin, HbA1c and lipid parameters were estimated.
  
  
  RESULTS
  Adiponectin concentration was not different in patients with type 2 diabetes mellitus and impaired glucose tolerance (n = 36) in comparison to the group with normal glucose tolerance (n = 26). There was also no difference in adiponectin concentration in relation to atherosclerosis progression. There was no significant correlation between adiponectin and calculated insulin resistance index, while there was marked inverse correlation between adiponectin and BMI (r = -0.30; p = 0.018), body weight (r = -0.33; p = 0.008), E-selectin (r = -0.263; p = 0.039), TG concentration (r = -0.27; p = 0.036), duration of coronary heart disease (r = -0.33; p = 0.009) and borderline significance with ejection fraction (r = -0.268; p = 0.06).
  
  
  CONCLUSIONS
  Our study supports the hypothesis that adiponectin could be recognised as a protective protein for the development of atherosclerosis.
authors.affiliation: Department of Endocrinology, Diabetology and Internal Medicine, Medical University of Białystok, ul. M. Skłodowskiej-Curie 24A, 15-276 Białystok, Poland. irinak@poczta.onet.pl
authors.forename: I
authors.initials: I
authors.lastname: Kowalska
authors.forename: M
authors.initials: M
authors.lastname: Straczkowski
authors.forename: A
authors.initials: A
authors.lastname: Nikołajuk
authors.forename: I
authors.initials: I
authors.lastname: Kinalska
authors.forename: M
authors.initials: M
authors.lastname: Górska
authors.forename: J
authors.initials: J
authors.lastname: Prokop
authors.forename: H
authors.initials: H
authors.lastname: Bachórzewska-Gajewska
authors.forename: W
authors.initials: W
authors.lastname: Musiał
mesh_terms: D052242:Adiponectin / Q000097:blood*; D000328:Adult; D001786:Blood Glucose / Q000032:analysis; D003327:Coronary Disease / Q000097:blood* / Q000378:metabolism; D003924:Diabetes Mellitus, Type 2 / Q000097:blood; D019040:E-Selectin / Q000097:blood*; D018149:Glucose Intolerance / Q000097:blood; D006801:Humans; D007333:Insulin Resistance; D008055:Lipids / Q000097:blood; D008297:Male; D008875:Middle Aged
chemical_list: D052242:Adiponectin; D001786:Blood Glucose; D019040:E-Selectin; D008055:Lipids